If you like what you have just read and want to receive at least 4 exclusive stock tips every week focused on Pharma, Biotech and Healthcare, then join me at my marketplace channel, Haggerston BioHealth . Invest alongside the model portfolio or simply access the investment bank-grade financial models and research. I hope to see you there.The group is for both novice and experienced biotech investors. It provides catalysts to look out for and buy and sell ratings. It also provides product sales and forecasts ...

Tandem Diabetes Care, Inc. (TNDM) posted a fourth-quarter 2024 loss of 44 cents per share compared with the year-ago quarter’s reported loss of 27 cents. The figure missed the Zacks Consensus Estimate of a loss of 25 cents per share.Find the latest EPS estimates and surprises on Zacks Earnings Calendar.On a GAAP basis, the company reported earnings of 1 cent per share compared to the year-ago loss of 46 cents.Full-year 2024 loss was $1.91 per share compared with the year-ago reported loss of $1.57. The figu ...

Financial Data and Key Metrics Changes - Annual worldwide sales reached a record $910 million, marking an 18% year-over-year increase [42] - Fourth quarter sales were $252 million, the largest in company history, with over 20% growth compared to the previous year [42] - Gross margin for 2024 was 51%, consistent with 2023, while adjusted EBITDA margin was negative 1% of sales [51][53] Business Line Data and Key Metrics Changes - In the U.S., pump shipments exceeded 24,000 in Q4, generating $184 million in sales, representing a 13% year-over-year growth [43] - Full year U.S. sales totaled $642 million, with nearly 81,000 pump shipments, a 10% increase [44] - Internationally, approximately 40,000 pumps were shipped for the full year, resulting in $268 million in sales, a 39% increase year-over-year [49] Market Data and Key Metrics Changes - The U.S. market saw strong performance from both t:slim and Mobi pump platforms, with significant growth in customers transitioning from multiple daily injections [19] - Outside the U.S., strong double-digit growth was driven by demand for the t:slim pump platform [19] - The company is transitioning to direct commercial operations in select European countries, expected to begin in 2026 [39] Company Strategy and Development Direction - The introduction of the Tandem Mobi pump platform is a key strategic focus, aimed at expanding the customer base and enhancing market presence [9][24] - The company is investing in a multichannel payer strategy to improve access and affordability for its products [16] - Plans for 2025 include launching new technology solutions and expanding the product portfolio, including the Sigi patch pump [63][67] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the underlying trends of the business despite challenges in Q4, including shipping delays and muted seasonality [20][78] - The company anticipates continued growth driven by renewals and new starts from MDI conversions, with expectations for a strong performance in 2025 [55] - The FDA's recent approval for Control-IQ+ for type 2 diabetes significantly expands the addressable market, positioning the company for long-term growth [15][117] Other Important Information - The company ended 2024 with $438 million in total cash and investments, indicating a strong financial position to support future commitments [53] - The Tandem Choice program concluded in Q4, allowing eligible customers to switch to Mobi, which will impact future sales recognition [48] Q&A Session All Questions and Answers Question: Can you quantify the Q4 shipping delays and December trends? - Management noted that the majority of the shortfall in Q4 was due to a muted seasonal curve in December, with shipping delays being a contributing factor but not the primary issue [76][78] Question: What are the next steps for the Pharmacy initiative? - The company is focused on driving scale and efficiency in the Pharmacy channel, having signed multiple contracts with leading PBMs, translating to approximately 20% of covered lives [84] Question: Will there be meaningful margin improvement from Mobi conversions this year? - Management confirmed that while Mobi's manufacturing costs are expected to improve, significant margin benefits from cartridges will begin in 2026 [88] Question: What new product innovations are included in the guidance for this year? - The guidance includes enhancements from Control-IQ+, integration with FreeStyle Libre 3, and the introduction of the Android app for Mobi [90][93] Question: How is the U.S. sales force expansion progressing? - The sales force expansion is nearly complete, with a focus on optimizing efficiencies and increasing share of voice in high-potential accounts [110][112] Question: What is the expected contribution from type 2 diabetes to new starts? - Management anticipates that type 2 diabetes could increase the percentage of new starts significantly, with a pilot launch planned for March [119][120]

Financial Performance - For the quarter ended December 2024, Tandem Diabetes Care, Inc. reported revenue of $252.45 million, reflecting a 28.3% increase year-over-year [1] - The earnings per share (EPS) was reported at -$0.44, compared to -$0.27 in the same quarter last year, indicating a decline [1] - The reported revenue was slightly below the Zacks Consensus Estimate of $255.18 million, resulting in a revenue surprise of -1.07% [1] - The company experienced an EPS surprise of -76.00%, with the consensus EPS estimate being -$0.25 [1] Key Metrics - Shares of Tandem Diabetes Care have returned -8.4% over the past month, while the Zacks S&P 500 composite changed by -2.3% [3] - The stock currently holds a Zacks Rank 3 (Hold), suggesting it may perform in line with the broader market in the near term [3] Geographic Sales - United States sales reached $214.56 million, exceeding the average estimate of $190.90 million by three analysts, representing a year-over-year increase of 42.2% [4] - Sales outside the United States were reported at $68.09 million, significantly surpassing the average estimate of $59.87 million, with a year-over-year change of 148291.5% [4] - Pump sales in the United States totaled $98.44 million, slightly below the average estimate of $101.47 million, marking a 19.5% year-over-year increase [4] - Supplies and other sales in the United States were $85.92 million, compared to the average estimate of $89.43 million, reflecting a 6% year-over-year change [4] - Pump sales outside the United States were $25.77 million, exceeding the average estimate of $19.85 million, with a year-over-year increase of 47.2% [4] - Supplies and other sales outside the United States reached $42.32 million, surpassing the average estimate of $40.50 million, indicating a 14.9% year-over-year change [4] - Total revenue from supplies and other was $128.24 million, slightly below the average estimate of $128.87 million [4] - Revenue from pumps was reported at $124.21 million, exceeding the average estimate of $121.53 million [4]

Tandem Diabetes Care, Inc. (TNDM) came out with a quarterly loss of $0.44 per share versus the Zacks Consensus Estimate of a loss of $0.25. This compares to loss of $0.27 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of -76%. A quarter ago, it was expected that this company would post a loss of $0.43 per share when it actually produced a loss of $0.36, delivering a surprise of 16.28%.Over the last four quarters, the company has ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 _________________________________________________________________ FORM 10-K _________________________________________________________________ ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2024 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-36189 ______ ...

Financial Performance - Worldwide GAAP sales grew 44% to $282.6 million in Q4 2024, while non-GAAP sales increased 21% to $252.4 million[3] - Full year 2024 GAAP sales reached $940.2 million, a 26% increase, with non-GAAP sales growing 18% to $910.0 million[3] - Gross profit for Q4 2024 was $157.5 million, with a GAAP gross margin of 56%, up from 47% in Q4 2023[6] - GAAP net income for Q4 2024 was $0.8 million, compared to a net loss of $30.0 million in Q4 2023[6] - Total sales for the three months ended December 31, 2024, reached $282.648 million, a 44% increase compared to $196.796 million in the same period of 2023[24] - Gross profit for the twelve months ended December 31, 2024, was $489.574 million, up from $367.690 million in 2023, reflecting a significant increase in profitability[24] - Operating loss for the three months ended December 31, 2024, was $581, a substantial improvement from a loss of $35.060 million in the same period of 2023[24] - Net income for the three months ended December 31, 2024, was $755, compared to a net loss of $30.002 million in the same period of 2023[24] - Non-GAAP sales for the twelve months ended December 31, 2024, were $909.954 million, an 18% increase from $772.825 million in 2023[29] Market and Product Developments - U.S. insulin pump market saw a double-digit increase in conversions from multiple daily injections[3] - The company received FDA clearance for Control-IQ+ to include individuals with type 2 diabetes[3] - Tandem Mobi pump shipments increased quarter-over-quarter throughout 2024[3] - The company reported a 20% increase in pump sales in the United States for the three months ended December 31, 2024, totaling $98.438 million compared to $82.364 million in 2023[26] Future Projections - For 2025, the company projects full year sales between $997 million and $1.007 billion, with U.S. sales estimated at $725 million to $730 million[10] - Gross margin for 2025 is estimated to be approximately 54% for the full year[10] Research and Development - The company signed a multi-year collaboration agreement with the University of Virginia Center for Diabetes Technology for R&D on automated insulin delivery systems[3] - Research and development expenses for the twelve months ended December 31, 2024, were $198.877 million, up from $169.667 million in 2023, reflecting the company's commitment to innovation[24] Financial Position - Total current assets decreased to $724.491 million as of December 31, 2024, from $747.989 million in 2023, primarily due to a decline in cash and cash equivalents[22] - Total liabilities increased to $704.560 million as of December 31, 2024, compared to $639.026 million in 2023, indicating a rise in financial obligations[22] - Total stockholders' equity decreased to $263.098 million as of December 31, 2024, from $313.632 million in 2023, indicating a reduction in the company's net worth[22]

Core Insights - Tandem Diabetes Care, Inc. (TNDM) is expected to report a quarterly loss of $0.25 per share, reflecting a 7.4% increase compared to the same period last year. Revenue is forecasted at $255.18 million, indicating a year-over-year increase of 29.7% [1] Financial Projections - Analysts estimate 'Sales- Pump- United States' to be $101.47 million, representing a 23.2% increase from the previous year [4] - 'Sales- Supplies and Other- United States' is projected at $89.43 million, showing a 10.3% increase year over year [4] - 'Geographic Sales- Outside the United States' is expected to reach $59.87 million, indicating a 30.5% year-over-year change [5] - 'Geographic Sales- United States' is forecasted at $190.90 million, reflecting a 26.5% increase from the prior year [5] - 'Sales- Supplies and Other- Outside the United States' is estimated at $40.50 million, suggesting a 10% year-over-year increase [6] - 'Sales- Pump- Outside the United States' is projected to be $19.85 million, indicating a 13.3% increase year over year [6] Market Performance - Shares of Tandem Diabetes Care have declined by 10.7% over the past month, while the Zacks S&P 500 composite has decreased by 1.8% [7] - TNDM holds a Zacks Rank of 3 (Hold), suggesting it is expected to perform in line with the overall market in the near future [7]

Core Viewpoint - Tandem Diabetes Care, Inc. (TNDM) has shown strong momentum with a 45.7% increase in share price over the past year, significantly outperforming the industry and the S&P 500, indicating solid growth potential for investors [1]. Company Overview - Tandem Diabetes designs, develops, and markets products for individuals with insulin-dependent diabetes, with its flagship product being the t:slim X2 Insulin Delivery System, recognized as the smallest durable insulin pump available [2]. - The company offers automated insulin delivery systems that integrate with multiple continuous glucose monitoring (CGM) sensors, along with a web-based data management platform and a mobile app, Sugarmate, for glucose data logging and notifications [3]. Factors Favoring Share Growth - The upward trend in TNDM's share price is driven by an expanding portfolio of delivery devices and applications, including the launch of Tandem Source, which enhances market opportunities [4]. - The integration of the t:slim X2 with Dexcom G7 and Lyumjev supports the company's market expansion efforts, bolstered by a strong third-quarter performance and increasing revenues [4]. Financial Performance - In the third quarter of 2024, Tandem Diabetes achieved record quarterly sales, attributed to positive feedback on the newly launched Tandem Mobi [6]. - The company reported an adjusted gross profit of $124.6 million, reflecting a 38.9% year-over-year increase, with gross margin improving by 274 basis points to 51.1% [7]. - Tandem Diabetes raised its revenue guidance for 2024 to a range of $903-$910 million, up from the previous estimate of $885-$892 million, indicating investor optimism [8]. Future Estimates - The company anticipates an earnings per share (EPS) growth rate of 28.8% for 2025, compared to the industry's 16.5% growth rate, with a Zacks Consensus Estimate for 2025 revenues at $1.01 billion, suggesting a 10.5% increase from the previous year [12].

Tandem Diabetes Care, Inc.’s (TNDM) impressive strategic initiatives are expected to bolster growth in the upcoming quarters. A robust diabetes market provides a favorable opportunity for the company’s growth. However, concerns loom over the adverse impact of macroeconomic challenges. Moreover, the company’s heavy dependence on insulin pumps is worrisome. In the past year, this Zacks Rank #3 (Hold) company’s shares have surged 44.8% compared with 7.3% growth of the industry and a 24.7% rise of the S&P 500 c ...